Ignite Creation Date:
2024-05-05 @ 5:17 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00426348
Status:
COMPLETED
Last Update Posted:
2013-08-28
First Post:
2007-01-23
Brief Title:
A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy
Sponsor:
Guangdong Provincial Peoples Hospital
Organization:
Guangdong Provincial Peoples Hospital
Study Overview
Official Title:
A Prospective Randomized Controlled Double Blinded Trial of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy
Status:
COMPLETED
Status Verified Date:
2013-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
a statement of the study hypothesisthe effect of valsartan in patients with IgA nephropathy have been provedand the efficacy of probucol in combination with valsartan is to be proved in patients with IgA nephropathy
This is a prospective randomized controlled double blinded pilot study to identify the efficacy of probucol in combination with valsartan in patients with IgA nephropathy The renal function deterioration will be the primary outcome studied The expected study duration will be 36 months
This is a prospective randomized controlled double blinded pilot study to identify the efficacy of probucol in combination with valsartan in patients with IgA nephropathy The renal function deterioration will be the primary outcome studied The expected study duration will be 36 months
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None